Clinical Trials Browser

Phase 2 × Solid Tumor × pemigatinib × Clear all

NCT06022289 2023-09-01

Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors

Phase 2 Unknown

Other solid neoplasm

Solid Tumor